Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose abiraterone with food in first-line treatment for metastatic hormone-resistant prostate cancer
TCTR20251118001Completed
- Sponsor
- N/A
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by N/A. Started Jan 2025; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on TCTR20251118001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251118001.